1932

Abstract

Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be inhibited by immunosuppressive mechanisms within the tumor, often through pathways outside of the currently targeted checkpoints. For this reason, only a minority of cancer patients achieve durable responses to current immunotherapies. Multiple novel approaches strive to expand immunotherapy's reach. These may include targeting alternative immune checkpoints. However, many investigational strategies look beyond checkpoint blockade. These include cellular therapies to bypass endogenous immunity and efforts to stimulate new adaptive antitumor responses using vaccines, adjuvants, and combinations with cytotoxic therapy, as well as strategies to inhibit innate immune suppression and modulate metabolism within the tumor microenvironment. The challenge for immunotherapy going forward will be to select rational strategies for overcoming barriers to effective antitumor responses from the myriad possible targets.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-030518-055552
2019-03-04
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/3/1/annurev-cancerbio-030518-055552.html?itemId=/content/journals/10.1146/annurev-cancerbio-030518-055552&mimeType=html&fmt=ahah

Literature Cited

  1. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G et al. 2013. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380–84
    [Google Scholar]
  2. Akalu YT, Rothlin CV, Ghosh S 2017. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol. Rev. 276:165–77
    [Google Scholar]
  3. Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA et al. 2014. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res 74:1670–81
    [Google Scholar]
  4. Ali SA, Shi V, Maric I, Wang M, Stroncek DF et al. 2016. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128:1688–700
    [Google Scholar]
  5. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N et al. 2015. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33:2780–88
    [Google Scholar]
  6. Bauer CA, Kim EY, Marangoni F, Carrizosa E, Claudio NM, Mempel TR 2014. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J. Clin. Investig. 124:2425–40
    [Google Scholar]
  7. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH 2016. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34:539–73
    [Google Scholar]
  8. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612–16
    [Google Scholar]
  9. Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K et al. 2017. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Investig. 127:929–41
    [Google Scholar]
  10. Bencherif SA, Warren Sands R, Ali OA, Li WA, Lewin SA et al. 2015. Injectable cryogel-based whole-cell cancer vaccines. Nat. Commun. 6:7556
    [Google Scholar]
  11. Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M et al. 2017. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat. Commun. 8:14278
    [Google Scholar]
  12. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ et al. 2018. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J. Clin. Oncol. 36:1714–68
    [Google Scholar]
  13. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR et al. 2016. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N. Engl. J. Med. 375:2561–69
    [Google Scholar]
  14. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S et al. 2013. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210:1685–93
    [Google Scholar]
  15. Byrne KT, Vonderheide RH 2016. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 15:2719–32
    [Google Scholar]
  16. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S et al. 2005. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202:1691–701
    [Google Scholar]
  17. Cekic C, Day YJ, Sag D, Linden J 2014. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 74:7250–59
    [Google Scholar]
  18. Chan AT, Arber N, Burn J, Chia WK, Elwood P et al. 2012. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. 5:164–78
    [Google Scholar]
  19. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS 2005. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914–23
    [Google Scholar]
  20. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ et al. 2004. A prospective study of aspirin use and the risk for colorectal adenoma. Ann. Intern. Med. 140:157–66
    [Google Scholar]
  21. Chan AT, Ogino S, Fuchs CS 2007. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356:2131–42
    [Google Scholar]
  22. Chan AT, Ogino S, Fuchs CS 2009. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649–58
    [Google Scholar]
  23. Chan YK, Gack MU 2016. Viral evasion of intracellular DNA and RNA sensing. Nat. Rev. Microbiol. 14:360–73
    [Google Scholar]
  24. Chao JL, Savage PA 2018. Unlocking the complexities of tumor-associated regulatory T cells. J. Immunol. 200:415–21
    [Google Scholar]
  25. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B et al. 2010. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699–713
    [Google Scholar]
  26. Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK et al. 2016. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22:680–90
    [Google Scholar]
  27. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC et al. 2016. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat. Med. 22:1411–20
    [Google Scholar]
  28. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM et al. 2017. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36:1658–67
    [Google Scholar]
  29. Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS et al. 2018. IAP antagonists enhance cytokine production from mouse and human iNKT cells. Cancer Immunol. Res. 6:25–35
    [Google Scholar]
  30. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT et al. 2015. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33:74–82
    [Google Scholar]
  31. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE et al. 2015. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11:1018–30
    [Google Scholar]
  32. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A et al. 2015. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161:1527–38
    [Google Scholar]
  33. Curran MA, Montalvo W, Yagita H, Allison JP 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS 107:4275–80
    [Google Scholar]
  34. de Metz J, Out TA, Wever PC, Reijneke RM, Sprangers F et al. 1999. Interferon-γ preferentially reduces memory/effector CD8 T lymphocytes in healthy subjects. J. Lab. Clin. Med. 134:147–53
    [Google Scholar]
  35. De Monte L, Reni M, Tassi E, Clavenna D, Papa I et al. 2011. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208:469–78
    [Google Scholar]
  36. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A et al. 2007. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13:4677–85
    [Google Scholar]
  37. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF et al. 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–86
    [Google Scholar]
  38. DiLillo DJ, Ravetch JV 2015. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol. Res. 3:704–13
    [Google Scholar]
  39. Dougan M. 2017. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front. Immunol. 8:1547
    [Google Scholar]
  40. Dougan M, Dougan SK 2017. Targeting immunotherapy to the tumor microenvironment. J. Cell. Biochem. 118:3049–54
    [Google Scholar]
  41. Dougan M, Dougan SK, Slisz J, Firestone B, Vanneman M et al. 2010. IAP inhibitors enhance co-stimulation to promote tumor immunity. J. Exp. Med. 207:2195–206
    [Google Scholar]
  42. Dougan M, Dranoff G 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27:83–117
    [Google Scholar]
  43. Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT et al. 2018. Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs. Cancer Immunol. Res. 6:389–401
    [Google Scholar]
  44. Dougan M, Li D, Neuberg D, Mihm M, Googe P et al. 2011. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J. Clin. Investig. 121:2436–46
    [Google Scholar]
  45. Dougan SK, Dougan M 2018. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy 9:787–96
    [Google Scholar]
  46. Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L et al. 2016. Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells. Cancer Immunol. Res. 4:621–30
    [Google Scholar]
  47. Dranoff G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4:11–22
    [Google Scholar]
  48. Dranoff G, Soiffer R, Lynch T, Mihm M, Jung K et al. 1997. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum. Gene. Ther. 8:111–23
    [Google Scholar]
  49. Dunn GP, Old LJ, Schreiber RD 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329–60
    [Google Scholar]
  50. Engblom C, Pfirschke C, Zilionis R, Da Silva Martins J, Bos SA et al. 2017. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:eaal5081
    [Google Scholar]
  51. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A et al. 2011. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475:226–30
    [Google Scholar]
  52. Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R et al. 2018. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124:3706–14
    [Google Scholar]
  53. Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y et al. 2018. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity. Science 359:1537–42
    [Google Scholar]
  54. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR et al. 2014. The cellular and molecular origin of tumor-associated macrophages. Science 344:921–25
    [Google Scholar]
  55. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM et al. 2018. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24:20–28
    [Google Scholar]
  56. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V et al. 1998. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–66
    [Google Scholar]
  57. Gabrilovich DI. 2017. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5:3–8
    [Google Scholar]
  58. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Estean E, Felip F et al. 2018. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378:2078–92
    [Google Scholar]
  59. Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A 2015. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 368:185–90
    [Google Scholar]
  60. Gao J, Shi LZ, Zhao H, Chen J, Xiong L et al. 2016. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397–404.e9
    [Google Scholar]
  61. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD et al. 2015. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373:1040–47
    [Google Scholar]
  62. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS et al. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372:2018–28
    [Google Scholar]
  63. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E et al. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919–29
    [Google Scholar]
  64. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR et al. 2016. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34:2389–97
    [Google Scholar]
  65. Goldberg MS. 2015. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 161:201–4
    [Google Scholar]
  66. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC et al. 2018. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103
    [Google Scholar]
  67. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL et al. 2013. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368:1509–18
    [Google Scholar]
  68. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ 2013. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 1:11–15
    [Google Scholar]
  69. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J et al. 2014. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2:632–42
    [Google Scholar]
  70. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711–23
    [Google Scholar]
  71. Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D et al. 2018. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front. Immunol. 9:151
    [Google Scholar]
  72. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA et al. 2015. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33:3193–98
    [Google Scholar]
  73. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA et al. 2007. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110:624–31
    [Google Scholar]
  74. Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI et al. 2017. Localized CD47 blockade enhances immunotherapy for murine melanoma. PNAS 114:10184–89
    [Google Scholar]
  75. Jiang H, Hegde S, DeNardo DG 2017. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol. Immunother. 66:1037–48
    [Google Scholar]
  76. Jinushi M, Hodi FS, Dranoff G 2006. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. PNAS 103:9190–95
    [Google Scholar]
  77. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH et al. 2008. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. PNAS 105:1285–90
    [Google Scholar]
  78. Johnson DB, Pectasides E, Feld E, Ye F, Zhao S et al. 2017. Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J. Immunother. 40:31–35
    [Google Scholar]
  79. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW et al. 2017. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 23:137–48
    [Google Scholar]
  80. Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC et al. 2017. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376:836–47
    [Google Scholar]
  81. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J et al. 2016. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J. Immunother. Cancer 4:12
    [Google Scholar]
  82. Kaufman HL, Kohlhapp FJ, Zloza A 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14:642–62
    [Google Scholar]
  83. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Investig. 121:4746–57
    [Google Scholar]
  84. Kohlhapp FJ, Kaufman HL 2016. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 22:1048–54
    [Google Scholar]
  85. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M et al. 2015. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692–96
    [Google Scholar]
  86. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A et al. 2016. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497–508
    [Google Scholar]
  87. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23–34
    [Google Scholar]
  88. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–18
    [Google Scholar]
  89. Lee L, Draper B, Chaplin N, Philip B, Chin M et al. 2018. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131:746–58
    [Google Scholar]
  90. Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G et al. 2010. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25. PNAS 107:2171–76
    [Google Scholar]
  91. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K et al. 2006. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12:6808–16
    [Google Scholar]
  92. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ 1992. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10:52–60
    [Google Scholar]
  93. Lim WA, June CH 2017. The principles of engineering immune cells to treat cancer. Cell 168:724–40
    [Google Scholar]
  94. Liu X, Pu Y, Cron K, Deng L, Kline J et al. 2015. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors. Nat. Med. 21:1209–15
    [Google Scholar]
  95. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL 2016. IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov 6:400–13
    [Google Scholar]
  96. Lu LL, Suscovich TJ, Fortune SM, Alter G 2018. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18:46–61
    [Google Scholar]
  97. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L et al. 2013. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38:729–41
    [Google Scholar]
  98. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC et al. 2013. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Investig. 123:2447–63
    [Google Scholar]
  99. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K et al. 2018. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–48
    [Google Scholar]
  100. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y et al. 2018. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104–8
    [Google Scholar]
  101. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM et al. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371:1507–17
    [Google Scholar]
  102. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M et al. 2018. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378:439–48
    [Google Scholar]
  103. McCracken MN, Cha AC, Weissman IL 2015. Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don't eat me” signals. Clin. Cancer Res. 21:3597–601
    [Google Scholar]
  104. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD 2013. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19:1044–53
    [Google Scholar]
  105. Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS et al. 2016. De-risking immunotherapy: report of a consensus workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol. Res. 4:279–88
    [Google Scholar]
  106. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y et al. 2011. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334:1573–77
    [Google Scholar]
  107. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M et al. 2016. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res 76:4372–82
    [Google Scholar]
  108. Mittal D, Young A, Stannard K, Yong M, Teng MW et al. 2014. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 74:3652–58
    [Google Scholar]
  109. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–93
    [Google Scholar]
  110. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR et al. 2016. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 34:3562–69
    [Google Scholar]
  111. Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ 2016. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. PNAS 113:6248–53
    [Google Scholar]
  112. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB et al. 2017. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377:2531–44
    [Google Scholar]
  113. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA et al. 2015. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J. Natl. Cancer Inst. 107:dju345
    [Google Scholar]
  114. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC 2018. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18:313–22
    [Google Scholar]
  115. Nicholas C, Lesinski GB 2011. Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 3:673–90
    [Google Scholar]
  116. Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ et al. 2017. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112–23
    [Google Scholar]
  117. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ et al. 2016. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–62
    [Google Scholar]
  118. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L et al. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54–61
    [Google Scholar]
  119. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D et al. 2006. A2A adenosine receptor protects tumors from antitumor T cells. PNAS 103:13132–37
    [Google Scholar]
  120. Ott PA, Hodi FS, Buchbinder EI 2015. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front. Oncol. 5:202
    [Google Scholar]
  121. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J et al. 2017. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217–21
    [Google Scholar]
  122. Park JH, Riviere I, Gonen M, Wang X, Senechal B et al. 2018. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378:449–59
    [Google Scholar]
  123. Payne KK, Bear HD, Manjili MH 2014. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol 10:1779–94
    [Google Scholar]
  124. Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C et al. 2016. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44:343–54
    [Google Scholar]
  125. Pitt JM, Kroemer G, Zitvogel L 2017. Immunogenic and non-immunogenic cell death in the tumor microenvironment. Adv. Exp. Med. Biol. 1036:65–79
    [Google Scholar]
  126. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366:925–31
    [Google Scholar]
  127. Postow MA, Callahan MK, Wolchok JD 2015. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33:1974–82
    [Google Scholar]
  128. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19:1264–72
    [Google Scholar]
  129. Pyzer AR, Avigan DE, Rosenblatt J 2014. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum. Vaccines Immunother. 10:3125–31
    [Google Scholar]
  130. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P et al. 2017. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390:1833–42
    [Google Scholar]
  131. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA et al. 2015. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21:1019–27
    [Google Scholar]
  132. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29:917–24
    [Google Scholar]
  133. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H et al. 2006. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12:4265–73
    [Google Scholar]
  134. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N 2015. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61
    [Google Scholar]
  135. Rosario M, Liu B, Kong L, Collins LI, Schneider SE et al. 2016. The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin. Cancer Res. 22:596–608
    [Google Scholar]
  136. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC et al. 2013. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19:3640–48
    [Google Scholar]
  137. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT et al. 2018. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97
    [Google Scholar]
  138. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M et al. 2017. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8:1136
    [Google Scholar]
  139. Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT et al. 2018. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 10:eaan4488
    [Google Scholar]
  140. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD et al. 2013. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 19:3404–15
    [Google Scholar]
  141. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R et al. 2017. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J. Clin. Oncol. 35:3807–14
    [Google Scholar]
  142. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M et al. 2016. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167:1125–36.e8
    [Google Scholar]
  143. Schumacher TN, Schreiber RD 2015. Neoantigens in cancer immunotherapy. Science 348:69–74
    [Google Scholar]
  144. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR et al. 2017. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377:2545–54
    [Google Scholar]
  145. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–23
    [Google Scholar]
  146. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210:1695–710
    [Google Scholar]
  147. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K et al. 2015. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–89
    [Google Scholar]
  148. Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ et al. 2016. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. PNAS 113:E2646–54
    [Google Scholar]
  149. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. PNAS 95:13141–46
    [Google Scholar]
  150. Sridharan V, Schoenfeld JD 2015. Immune effects of targeted radiation therapy for cancer. Discov. Med. 19:219–28
    [Google Scholar]
  151. Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN et al. 2015. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28:638–52
    [Google Scholar]
  152. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P et al. 2017. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J. Clin. Oncol. 35:3815–22
    [Google Scholar]
  153. Taniguchi K, Karin M 2018. NF-κB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18:309–24
    [Google Scholar]
  154. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J et al. 2018. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554:538–43
    [Google Scholar]
  155. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N et al. 2013. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539–49
    [Google Scholar]
  156. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447–57
    [Google Scholar]
  157. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB et al. 2015. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33:773–81
    [Google Scholar]
  158. Topalian SL, Drake CG, Pardoll DM 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–61
    [Google Scholar]
  159. Tran E, Robbins PF, Rosenberg SA 2017. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18:255–62
    [Google Scholar]
  160. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641–45
    [Google Scholar]
  161. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE et al. 2015. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–77
    [Google Scholar]
  162. Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T et al. 2017. Clinical dosing regimen of selinexor maintains normal immune homeostasis and T-cell effector function in mice: implications for combination with immunotherapy. Mol. Cancer Ther. 16:428–39
    [Google Scholar]
  163. van Elsas A, Hurwitz AA, Allison JP 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355–66
    [Google Scholar]
  164. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS et al. 2015. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 75:2232–42
    [Google Scholar]
  165. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N et al. 2015. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079–84
    [Google Scholar]
  166. Vijayan D, Young A, Teng MWL, Smyth MJ 2017. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17:709–24
    [Google Scholar]
  167. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK et al. 2014. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20:5290–301
    [Google Scholar]
  168. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS et al. 2014. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2:154–66
    [Google Scholar]
  169. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM et al. 2013. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88–91
    [Google Scholar]
  170. Wong KK, Li WA, Mooney DJ, Dranoff G 2016. Advances in therapeutic cancer vaccines. Adv. Immunol. 130:191–249
    [Google Scholar]
  171. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C et al. 2014. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 21:69–78
    [Google Scholar]
  172. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C et al. 2016. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30:391–403
    [Google Scholar]
  173. Zang X, Allison JP 2007. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13:5271–79
    [Google Scholar]
  174. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W et al. 2016. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:819–29
    [Google Scholar]
  175. Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R et al. 2015. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27:489–501
    [Google Scholar]
  176. Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL et al. 2017. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47:323–38.e6
    [Google Scholar]
  177. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL et al. 2014. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–69
    [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-030518-055552
Loading
/content/journals/10.1146/annurev-cancerbio-030518-055552
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error